Immunizations

The FDA has authorized a single booster dose for individuals aged 5 to 11 years old at least five months after completion of a primary series with the Pfizer-BioNTech COVID-19 vaccine.

Moderna's submission to the FDA is based on Phase 2/3 studies of mRNA-1273 in young children.

The Austin Public Health department of Austin, Texas has become the nation’s first health department recipient of the firm’s Exemplary Provider Certification program for Immunization and Testing Services.

This allocation effort is a part of the Federal Retail Pharmacy Program for COVID-19 Vaccination, which includes Good Neighbor Pharmacy.

The FDA authorized a second booster dose in adults aged 50 years old and older and for those aged 12 years old and older with compromised immune systems.

Moderna said that it will submit a request for authorization of a 25 μg two-dose primary series of mRNA-1273 for children aged 6 months old to under 6 years old to the FDA, EMA and other global regulators in the coming weeks.

Thirty-five generic manufacturers have signed agreements with the MPP to produce low-cost, generic versions of Pfizer’s oral COVID-19 treatment nirmatrelvir in combination with ritonavir for 95 low- and middle-income countries.

The services, made possible under the Public Readiness and Emergency Preparedness Act, relate to COVID-19 tests, vaccinations and therapeutics, childhood vaccinations, and flu vaccinations.